KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Assets (2016 - 2026)

NovoCure's Non-Current Assets history spans 13 years, with the latest figure at $156.3 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 2.03% to $156.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $156.3 million, a 2.03% decrease, with the full-year FY2025 number at $157.6 million, up 17.43% from a year prior.
  • Non-Current Assets hit $156.3 million in Q1 2026 for NovoCure, down from $157.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for NVCR hit a ceiling of $162.6 million in Q2 2025 and a floor of $68.1 million in Q2 2022.
  • Historically, Non-Current Assets has averaged $116.2 million across 5 years, with a median of $118.7 million in 2024.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 39.64% in 2022 and later fell 2.03% in 2026.
  • Tracing NVCR's Non-Current Assets over 5 years: stood at $80.1 million in 2022, then soared by 39.44% to $111.7 million in 2023, then rose by 20.13% to $134.2 million in 2024, then increased by 17.43% to $157.6 million in 2025, then decreased by 0.85% to $156.3 million in 2026.
  • Business Quant data shows Non-Current Assets for NVCR at $156.3 million in Q1 2026, $157.6 million in Q4 2025, and $161.3 million in Q3 2025.